Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans
© Ebbert et al; licensee BioMed Central Ltd. 2011
Received: 21 October 2011
Accepted: 23 December 2011
Published: 23 December 2011
Multivariate assays (MVAs) for assisting clinical decisions are becoming commonly available, but due to complexity, are often considered a high-risk approach. A key concern is that uncertainty on the assay's final results is not well understood. This study focuses on developing a process to characterize error introduced in the MVA's results from the intrinsic error in the laboratory process: sample preparation and measurement of the contributing factors, such as gene expression.
Using the PAM50 Breast Cancer Intrinsic Classifier, we show how to characterize error within an MVA, and how these errors may affect results reported to clinicians. First we estimated the error distribution for measured factors within the PAM50 assay by performing repeated measures on four archetypal samples representative of the major breast cancer tumor subtypes. Then, using the error distributions and the original archetypal sample data, we used Monte Carlo simulations to generate a sufficient number of simulated samples. The effect of these errors on the PAM50 tumor subtype classification was estimated by measuring subtype reproducibility after classifying all simulated samples. Subtype reproducibility was measured as the percentage of simulated samples classified identically to the parent sample. The simulation was thereafter repeated on a large, independent data set of samples from the GEICAM 9906 clinical trial. Simulated samples from the GEICAM sample set were used to explore a more realistic scenario where, unlike archetypal samples, many samples are not easily classified.
All simulated samples derived from the archetypal samples were classified identically to the parent sample. Subtypes for simulated samples from the GEICAM set were also highly reproducible, but there were a non-negligible number of samples that exhibit significant variability in their classification.
We have developed a general methodology to estimate the effects of intrinsic errors within MVAs. We have applied the method to the PAM50 assay, showing that the PAM50 results are resilient to intrinsic errors within the assay, but also finding that in non-archetypal samples, experimental errors can lead to quite different classification of a tumor. Finally we propose a way to provide the uncertainty information in a usable way for clinicians.
KeywordsMultivariate Assays PAM50 Monte Carlo Simulations Breast Cancer
Multivariate assays (MVAs) using gene expression as their contributing factors are becoming commonly used in assisting treatment decisions in medicine, especially in oncology. Examples of MVAs available for planning breast cancer treatment include the 55-gene subtype classifier (PAM50 Breast Cancer Intrinsic Classifier) , the 21-gene prognosis assay (Oncotype DX®) , the 14-gene prognosis assay (BreastOncPx™)  and the 70-gene prognosis assay (MammaPrint®) . Though physicians may rely on these MVAs for planning treatment, little is known about the effects on the results of an assay due to the intrinsic error in the laboratory process and measuring its contributing factors - in this case, all steps required for preparing a sample (post RNA extraction), preparing the assay, and the instrumental errors for measuring gene expression. While we expect that classification of samples in proximity to one of the centroids defining the tumor classes, which we will call archetypal samples here, will be very stable with respect to experimental errors in the gene expression measurements, what happens to the samples not in proximity to one centroid is unknown. For example, if a sample lies in a "gray" area where the intrinsic errors in the gene expression measurements may result in a change of its classification each time the sample is run, the results reported to the attending physician may be misleading because he/she is getting the results from only one measurement and no information about the probability for sample misclassification. Given the serious consequences due to ambiguous results in clinical classifications, methods to measure the effects of an MVA's intrinsic errors need to be established and communicated to attending physicians.
The PAM50 assay measures the expression level of 55 genes (50 classifier genes and 5 housekeepers) creating a "signature" that is compared, using Spearman's Rho as a distance measure, to each of five centroids [1, 5] representing the Luminal A, Luminal B, HER2-enriched and Basal-like subtypes [1, 6, 7], as well as Normal-like tissue.
The complexity of the PAM50 assay demonstrates the challenge of identifying and understanding error sources from the moment a sample is received by the reference laboratory until a clinical report is generated. Error sources to be considered include heterogeneity and sample preparation, as well as technical variability, which may be separated into error from measuring devices as well as intrinsic and explicit classification uncertainties. While the overall purpose of this project is to develop a model for estimating the effect of all error sources on final MVA results, in this paper we focus on how to estimate the effect that intrinsic gene expression measurement errors, including those associated with sample and assay preparation, have on the classification of tumors.
A comprehensive experimental study to estimate the effect that the intrinsic gene expression measurement errors have on the classification of tumors and gene-score classifications requires, in principle, repeated testing of a significant number of samples from each subtype and thorough analysis of the misclassifications observed. Such a comprehensive approach is unfeasible in terms of cost and sample availability. Here we have adopted a hybrid approach in which we perform repeated experimental measurements on one sample from each subtype (i.e. Luminal A, Luminal B, HER2-enriched and Basal-like) to determine the experimental variability of the measured gene expression for each of the 50 genes included in the PAM50 assay. Using this experimental information we proceed to generate a Gaussian error distribution that can be used to generate multiple data sets by way of Monte Carlo simulations. These simulations impose random errors, given by the Gaussian distribution, on the set of experimental measured samples. Monte Carlo simulations are well suited for this hybrid analysis because there is extensive literature for using this approach to estimate errors in high-dimensional problems, such as fluids and thermodynamics [8–10], where conventional analytics are not feasible [11, 12]. The simulated data sets are then classified by the standard PAM50 algorithm, and the misclassifications encountered in the synthetic data sets are used as a proxy for the PAM50's misclassification rate based on the assay's intrinsic error.
Specifically, in this study we followed five major steps: (1) collect and prepare four archetypal samples representative of each cancer subtype; (2) characterize the intrinsic error for each gene's expression values in the assay by making twelve measurements for each gene's expression on each archetypal sample and determine the distribution type that best models the experimental errors; (3) using Monte Carlo simulations generate a sufficient number of simulated test samples, based on a defined confidence interval width, by imposing the errors generated using the distribution from (2) onto the archetypal samples; (4) determine the effect of the variability imposed in the simulated samples on their classification; and (5) repeat steps (3) and (4) on an independent set of samples from the GEICAM 9906 clinical trial (GEICAM) .
Archetypal Sample Collection and Preparation
In order to characterize the error in gene expression measurements, four archetypal samples representative of each cancer subtype with sufficient genetic material were constructed - since most single samples do not have enough genetic material to be tested more than twice. Cell lines representative of Basal-like (ME16C) and Luminal B (MCF7) subtypes were grown in the Reagent Lab at ARUP Laboratories. Luminal A and HER2-enriched subtypes were not readily available as a cell lines. As such, 20 patient tumor samples previously identified as archetypal Luminal A (10 samples) and HER2-enriched (10 samples), based on PAM50 gene scores and classification, were collected under IRB approved protocols at the University of Utah to be combined and treated as single tumor samples.
RNA was extracted from tumor-enriched areas of formalin-fixed, paraffin-embedded (FFPE) tissue blocks, containing more than 70% tumor cells, as determined during review by a board-certified pathologist. Samples were deparaffinized using Citrus Clearing Solvent (Richard-Allen Scientific, Kalamazoo, MI, http://www.thermofisher.com) followed by dehydration in absolute ethanol. RNA extraction was completed on a Biomek NX Laboratory Automation Workstation (Beckman Coulter, Beverly, MA, http://www.beckmancoulter.com) using the AgenCourt FormaPure Kit (Beckman Coulter, Beverly, MA, http://www.beckmancoulter.com) according to the manufacturer's instructions and including a DNase I step. RNA quantification was done on a Paradigm Detection Platform (Beckman Coulter, Beverly, MA, http://www.beckmancoulter.com) using the Quant-iT RiboGreen Assay Kit (Invitrogen, Carlsbad, CA, http://www.invitrogen.com). cDNA synthesis was performed on the Biomek FX Laboratory Automation Workstation (Beckman Coulter, Beverly, MA, http://www.beckmancoulter.com) using 600 ng of RNA, uracil containing dNTPs (Invitrogen, Carlsbad, CA, http://www.invitrogen.com), random primers (Invitrogen, Carlsbad, CA, http://www.invitrogen.com), gene-specific, downstream PCR primers (Idaho Technology, Salt Lake City, UT, http://www.idahotech.com ), and SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, http://www.invitrogen.com ).
Each 5 μL reaction contained 1X LightCycler 480 SYBR Green I Master Mix (Roche Applied Sciences, Indianapolis, IN, http://www.roche-applied-science.com) and 1.67 ng cDNA were added to the experimental sample wells. Sample cDNA was incubated with LightCycler Uracil-DNA Glycosylase (Roche Applied Sciences, Indianapolis, IN, http://www.roche-applied-science.com) at 40°C for 10 min and inactivated at 95°C for 10 min prior to performing Real-time, quantitative PCR (RT-qPCR). RT-qPCR was performed on the LightCycler (LC) 480 (Roche Applied Sciences, Indianapolis, IN, http://www.roche-applied-science.com) as follows: 45 cycles at 95°C for 4 sec, 58°C for 6 sec and 72°C for 6 sec. To assure target specificity, RT-qPCR was followed by a melting curve analysis: 95°C for 15 sec, 65°C for 1 min followed by raising the temperature to 99°C while taking 10 fluorescence acquisitions/°C. We then classified the RT-qPCR data from each run. One run from the Luminal A sample failed quality control and was not included in further analysis.
Sample Size Justification for Archetypal Sample Monte Carlo Simulation
level (Z0.05 = 1.96), expected proportion of misclassifications (θ = 0.02) and the sample size, or in this case, the number of simulations (n = 100,000). The calculated confidence interval width is ± 0.00087 for each simulation of 100,000 samples, which is an acceptable value.
Monte Carlo Simulation Using Archetypal Samples
Monte Carlo simulations were performed using the mean (μ) value and standard deviation (σ) for the expression of each gene within the archetypal samples, as described above. This procedure created a total of two hundred independent distributions, i.e. fifty Gaussian distributions (one for each gene) for each of the four archetypal samples. For example, the mean expression value (μ) for ACTR3B from the twelve Luminal B values was 1.94 and the corresponding standard deviation (σ) was 0.085. Therefore the ACTR3B expression value for each of the 100,000 simulated Luminal B samples was randomly selected from a Gaussian distribution centered on a mean (μ) of 1.94 and with a standard deviation (σ) of 0.085. Randomly selecting a value from the Gaussian distribution, as described, does not assume gene expression values are independent of one another, rather the method assumes that the measurement error for each gene is independent. Specifically, since each Gaussian distribution is centered on the gene's mean expression value for the given sample, any genes within the sample that are generally upregulated will all be generally upregulated in the simulated samples, while allowing the error to deviate independently. The 100,000 simulated samples for each archetypal sample were classified using the standard PAM50 process. The effect of intrinsic gene expression measurement error on the tumor classification was assessed by determining the percentage of simulated samples that were classified identically to the original sample. This value provides an estimate of the reproducibility of the results for archetypal samples.
Evaluation Using the GEICAM Larger and Independent Test Set
Testing archetypal samples is valuable for determining how the PAM50 assay will perform under ideal circumstances, but these results may not be informative when the samples are not as well characterized as the archetypal samples. Thus, the method described above for the archetypal samples was adapted and applied to the larger and more diverse set of independent samples from the GEICAM 9906 clinical trial. A total of 911 breast tumors collected by the GEICAM group for the GEICAM 9906 clinical trial were run and classified by the PAM50. Tumor samples were prepared following the same methods described above for the archetypal samples and those with insufficient tumor content to be classified were excluded from further analyses.
Monte Carlo Simulation Using GEICAM Samples
The model described above was used to generate random variants of the 847 GEICAM samples remaining after excluding those that could not be classified. The subtype classification reproducibility for each GEICAM sample was tested by generating 100,000 simulated samples using Monte Carlo simulations for each of the error models considered above, i.e. "best-," "average-" and "worst-case," for a total of 300,000 simulated samples per GEICAM sample. Based on the same sample justification analysis used for the archetypal samples, the calculated confidence interval width is ± 0.00087 for each simulation of 100,000 samples, which is an acceptable value.
Error Effect on PAM50 Results for GEICAM Samples
After simulating 300,000 samples for each GEICAM sample based on the error models described above, subtype reproducibility for the individual samples was summarized for each tumor subtype (based on the original sample's subtype) using two statistics: (1) the total percentage of simulated samples that did (or did not) change subtypes with respect to their parent sample and (2) the proportion of simulated samples, corresponding to a single original sample, that were classified (or misclassified) identically to the parent sample. These data serve as an estimate of PAM50's misclassification rate based on intrinsic error within the assay when samples are not in proximity to the PAM50 centroids.
Results and Discussion
All simulated samples derived from the archetypal samples were classified the same subtype as the parent sample, indicating that the PAM50 subtype classification for samples with characteristics close to the PAM50 centroids is highly reproducible and resilient to experimental errors in gene expression measurements. Although this positive result is encouraging for PAM50 classifications, it is not generalizable beyond the four archetypal samples.
GEICAM 9906 Samples
Original GEICAM Sample Subtype vs Simulated Sample Subtype (as Percentage) - Best-Case Scenario
Classified as Subtype (%)
Luminal A (303000)
Luminal B (270000)
Original GEICAM Sample Subtype vs. Simulated Sample Subtype (as Percentage) - Average-Case Scenario
Classified as Subtype (%)
Luminal A (303000)
Luminal B (270000)
Original GEICAM Sample Subtype vs. Simulated Sample Subtype (as Percentage) - Worst-Case Scenario
Classified as Subtype (%)
Luminal A (303000)
Luminal B (270000)
Results for the GEICAM sample simulations suggest that all subtype classes are highly reproducible. When considering the three different error models, the most reproducible subtype among all GEICAM samples was always the Basal-like for which 98.47% (average-case) of the simulated samples did not change classification, followed by Luminal B (96.63%, average-case), Luminal A (95.46%, average-case) and HER2-enriched (90.07%, average-case). The differences in reproducibility between "best-" and "worst-case" ("best-case" percentages minus "worst-case" percentages) are 0.89%, 1.31%, 1.31% and 4.35% for Basal-like, Luminal B, Luminal A and HER2-enriched, respectively. Therefore, the selection of the error model is not a determining factor in assessing the robustness of the classification due to experimental errors in gene expression measurement.
We have developed a method based on Monte Carlo simulations and limited experimental measurements to estimate the effect of the intrinsic experimental errors in the measured factors contributing to MVAs. While the specifics of the error distribution functions given in Additional file 1 are not universal functions and they have to be recalculated for each lab and/or experimental setting, the method proposed here is generalizable and can be adapted to any MVA.
Using the proposed method based on Monte Carlo simulations and the error model described here, we have presented data that suggests PAM50's subtype classifications are highly reproducible on a large, independent sample set from the GEICAM 9906 clinical trial. We also show that there are a non-negligible number of samples for which a significant number of the Monte Carlo simulated samples classify differently than the parent sample, indicating that the classification of the original sample may not be reliable. To address this problem we suggest a new score card that can inform clinicians on the probability that a particular sample could be classified as a different tumor subtype.
Authors acknowledge National Library of Medicine for training grant LM007124 and the Reagent Lab of the ARUP Institute for Clinical and Experimental Pathology for providing cell lines used in the study. Also, an allocation of computer time from the Center for High Performance Computing at the University of Utah is gratefully acknowledged.
- Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology. 2009, 27: 1160-1167. 10.1200/JCO.2008.18.1370.PubMed CentralView ArticlePubMedGoogle Scholar
- Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. New England Journal of Medicine. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.View ArticlePubMedGoogle Scholar
- Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F: Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer. 2008, 8: 339-10.1186/1471-2407-8-339.PubMed CentralView ArticlePubMedGoogle Scholar
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.View ArticlePubMedGoogle Scholar
- Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002, 99: 6567-72. 10.1073/pnas.082099299.PubMed CentralView ArticlePubMedGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-52. 10.1038/35021093.View ArticlePubMedGoogle Scholar
- Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-74. 10.1073/pnas.191367098.PubMed CentralView ArticlePubMedGoogle Scholar
- Metropolis N: The Beginning of the Monte Carlo Method. Los Alamos Science. 1987, 125-130.Google Scholar
- Panagiotopoulos A: Direct determination of phase coexistence properties of fluids by Monte Carlo simulation in a new ensemble. Molecular Physics. 1987, 61: 813-826. 10.1080/00268978700101491.View ArticleGoogle Scholar
- Ehrman JR, Fosdick LD, Handscomb DC: Computation of Order Parameters in an Ising Lattice by the Monte Carlo Method. J Math Phys. 1960, 1: 547-10.1063/1.1703692.View ArticleGoogle Scholar
- Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E: Equation of State Calculations by Fast Computing Machines. J Chem Phys. 1953, 21: 1087-10.1063/1.1699114.View ArticleGoogle Scholar
- Hastings WK: Monte Carlo sampling methods using Markov chains and their applications. Biometrika. 1970, 57: 97-109. 10.1093/biomet/57.1.97.View ArticleGoogle Scholar
- Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, Lopez Garcia-Asenjo JA, Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, Alvarez JV, Garcia Puche JL, Sanchez-Rovira P, Gonzalez S, Lopez-Vega JM: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008, 100: 805-14. 10.1093/jnci/djn151.View ArticlePubMedGoogle Scholar
- R Development Core Team: R: A Language and Environment for Statistical Computing. 2011, Vienna, Austria: R Foundation for Statistical ComputingGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.